Back
ESC Premium Access

Modified frailty as a novel factor to predict the effectiveness of electrical cardioversion of atrial fibrillation in the elderly population

Session: Poster Session 2 - Drug treatment for atrial fibrillation
Topic: Rhythm Control, Cardioversion
Speaker: Associate Professor A. Mlynarska (Katowice, PL)
Event: ESC Congress 2019

Congress Presentation

About the speaker

Associate Professor Agnieszka Mlynarska

Medical University of Silesia, Katowice (Poland)
1 presentation
1 follower

9 more presentations in this session

Prevalence and risk of DOACs inappropriate dosing in atrial fibrillation. An analysis of the Swiss-AF and BEAT-AF registries

Speaker: Doctor G. Montrasio (London, GB)

Access
Abstract
Slides
Thumbnail

Heparin and low-molecular-weight heparin switch associated with an increase in bleeding complications in patients on apixaban undergoing catheter ablation: The AMPER ABLATION study

Speaker: Doctor W. Amara (Le Raincy-Montfermeil, FR)

Access
Abstract
Thumbnail

Amiodarone treatment duration and reasons for permanent drug discontinuation in patients with atrial fibrillation

Speaker: Doctor M. Mihajlovic (Belgrade, RS)

Access
Abstract
Slides
Thumbnail

Use of direct thrombin inhibitor on the day of atrial fibrillation ablation decreases incidence of silent cerebral ischemia detected by magnetic resonance imaging

Speaker: Associate Professor M. Harada (Toyoake, JP)

Access
Abstract
Thumbnail

Comparison of efficacy of different anticoagulation strategies used during pulmonary vein isolation in left atrial blood samples

Speaker: Doctor O. Hajas (Debrecen, HU)

Access
Abstract
Slides
Thumbnail

Access the full session

Poster Session 2 - Drug treatment for atrial fibrillation

Speakers: Associate Professor A. Mlynarska, Doctor G. Montrasio, Doctor W. Amara, Doctor M. Mihajlovic, Associate Professor M. Harada...
Access
Thumbnail

About the event

Image

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb